Application of isorhodanic ester type compound to prevention and/or treatment of hyperbilirubinemia

A technology for hyperbilirubinemia and compounds, applied in the direction of silicon compound active ingredients, ester active ingredients, medical preparations containing active ingredients, etc.

Inactive Publication Date: 2017-10-31
JC (WUXI) CO INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For this group of people, there are curren...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of isorhodanic ester type compound to prevention and/or treatment of hyperbilirubinemia
  • Application of isorhodanic ester type compound to prevention and/or treatment of hyperbilirubinemia
  • Application of isorhodanic ester type compound to prevention and/or treatment of hyperbilirubinemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0151] Example 1 The study of reducing total bilirubin activity and blood lipids in patients with benign prostatic hyperplasia

[0152] Experimental purpose: To study the clinical efficacy and safety of oral phenethyl isothiocyanate capsules in the treatment of benign prostatic hyperplasia (BPH).

[0153] Experimental design: A multi-center, randomized, double-blind, placebo-controlled design was used to preliminarily evaluate the safety and effectiveness of phenylethyl isothiocyanate capsules in the treatment of BPH patients.

[0154] Subjects who met the inclusion and exclusion criteria were randomly assigned to any of the following four groups according to the ratio of 1:1:1:1: Group A: phenylethyl isothiocyanate 10 mg / time, 3 times a day group D: phenylethyl isothiocyanate 20mg / time, 3 times a day; group B: phenylethyl isothiocyanate 30mg / time, 3 times a day; group C: phenethyl isothiocyanate Cyanate placebo 1 capsule / time, 3 times a day. Oral administration, the course ...

Embodiment 2

[0198] Example 2 Auxiliary detection of total bilirubin and blood lipids

[0199] Using the same method as in Example 1, 24 volunteers with benign prostatic hyperplasia and hyperbilirubinemia were recruited from the medical research colleagues. In the same manner as in Example 1, subjects who met the inclusion and exclusion criteria were randomly assigned to any of the following four groups in a ratio of 1:1:1:1: Administration group (Group A): Benzene Ethyl isothiocyanate 10mg / time, 3 times a day; administration group (group D): phenylethyl isothiocyanate 20mg / time, 3 times a day; administration group (group B): benzene Ethyl isothiocyanate 30mg / time, 3 times a day; placebo group (group C): phenethyl isothiocyanate placebo 1 capsule / time, 3 times a day. Oral administration, the course of treatment is 24 weeks.

[0200] Evaluate the effectiveness and safety of the experiment. Effectiveness: ①Benign prostatic hyperplasia: IPSS, QOL, prostate volume, maximum urinary flow rate...

Embodiment 3

[0202] Example 3 Auxiliary detection of total bilirubin

[0203] The method is the same as in Example 2, the difference is that 8 volunteers who only suffer from hyperbilirubinemia are recruited from the medical research colleagues.

[0204] In the same manner as in Example 2, the subjects were randomly assigned to any one of the following four groups in a ratio of 1:1:1:1: administration group (group A): phenylethyl isothiocyanate Ester 10mg / time, 3 times a day; administration group (group D): phenylethyl isothiocyanate 20mg / time, 3 times a day; administration group (group B): phenethyl isothiocyanate Ester 30mg / time, 3 times a day; placebo group (Group C): phenethyl isothiocyanate placebo 1 capsule / time, 3 times a day. Oral administration, the course of treatment is 6 weeks.

[0205] The results show that after the volunteers take the isothiocyanate compound (such as phenylethyl isothiocyanate) of the present invention, the total bilirubin level is significantly decreased,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of isothiocyanate compounds in the prevention and/or treatment of hyperbilirubinemia, specifically, the invention discloses a compound represented by formula (I) or a compound represented by formula (II) Use of the indicated derivatives for the preparation of compositions or preparations for the prevention and/or treatment of hyperbilirubinemia. The compound of the present invention can not only effectively treat hyperbilirubinemia, but also significantly reduce the total bilirubin level in mammalian (such as human) serum. At the same time, it is unexpectedly found that it can also effectively treat hyperlipidemia , and can significantly reduce the level of triglyceride and low-density lipoprotein in serum of mammals (such as rats and humans), while increasing the level of high-density lipoprotein in serum.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of isothiocyanate compounds in the prevention and / or treatment of hyperbilirubinemia. Background technique [0002] Most of the bilirubin in the serum is derived from the hemoglobin produced after the destruction of aging red blood cells. The glucuronidated bilirubin in the liver is called direct bilirubin, and the glucuronidated bilirubin in the liver is called indirect bilirubin. The sum of the two is total bilirubin. [0003] Clinically, the test of bilirubin is mainly used for the diagnosis of liver disease and biliary obstruction. When the total serum bilirubin is greatly increased, the human skin, eye sclera, urine and serum appear yellow, so it is called jaundice, that is, hyperbilirubinemia. When liver inflammation, necrosis, poisoning and other damages can cause jaundice, biliary tract disease and hemolytic disease can also cause jaundice. Mainly direct bilirub...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/26A61K31/655A61K31/5375A61K31/277A61K31/695A61K45/06A61P1/16A61P3/06A23L33/10
CPCA61K31/26A61K31/277A61K31/5375A61K31/655A61K31/695A61K45/06
Inventor 程景才张春侠程志维
Owner JC (WUXI) CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap